[PDF][PDF] Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus
…, N Smith, RM Tucker, D Wang, MD Wyles, C McDanal… - Cell, 2020 - cell.com
A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become
the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies …
the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies …
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
…, F Castellino, B Flach, BC Lin, S O'Connell, C McDanal… - Science, 2022 - science.org
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
…, TK Greenwell, CB McDanal… - Proceedings of the …, 1994 - National Acad Sciences
To define the role of the human immunodeficiency virus type 1 (HIV-1) envelope proteins in
virus infection, a series of peptides were synthesized based on various regions of the HIV-1 …
virus infection, a series of peptides were synthesized based on various regions of the HIV-1 …
[HTML][HTML] SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination
…, SD Schmidt, S O'Dell, C McDanal… - … England Journal of …, 2022 - Mass Medical Soc
Omicron Neutralization and mRNA-1273 Boosters Neutralization of the omicron variant was
assessed in serum samples obtained from persons who had received an mRNA-1273 …
assessed in serum samples obtained from persons who had received an mRNA-1273 …
[HTML][HTML] SARS-CoV-2 variant B. 1.1. 7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of
generating protective neutralizing antibodies. The recent emergence and rapid spread of several …
generating protective neutralizing antibodies. The recent emergence and rapid spread of several …
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
C Wild, T Oas, C McDanal… - Proceedings of the …, 1992 - National Acad Sciences
A peptide designated DP-107 was synthesized containing amino acid residues 558-595 of
the envelope glycoprotein gp160 of human immunodeficiency virus type 1 strain LAI (HIV-…
the envelope glycoprotein gp160 of human immunodeficiency virus type 1 strain LAI (HIV-…
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
…, SN Shah, VV Edara, K Floyd, L Lai, C McDanal… - Science, 2021 - science.org
INTRODUCTION Mass vaccination against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) offers the most efficient public health intervention to control the COVID-19 …
2 (SARS-CoV-2) offers the most efficient public health intervention to control the COVID-19 …
[PDF][PDF] D614G spike mutation increases SARS CoV-2 susceptibility to neutralization
…, S Santra, K Mansouri, S Gobeil, C McDanal… - Cell host & …, 2021 - cell.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired
a D614G mutation early in the pandemic that confers greater infectivity and is now the …
a D614G mutation early in the pandemic that confers greater infectivity and is now the …
[PDF][PDF] In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
…, X Lu, R Parks, LL Sutherland, TH Oguin, C McDanal… - Cell, 2021 - cell.com
SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding
SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated …
SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated …
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
…, AJ Langlois, C McDanal… - Proceedings of the …, 1989 - National Acad Sciences
The principal neutralizing determinant of human immunodeficiency virus type 1 (HIV-1) is
located in the external envelope protein, gp120, and has previously been mapped to a 24-…
located in the external envelope protein, gp120, and has previously been mapped to a 24-…